Review Article
Pulmonary Arterial Hypertension in Adults: Novel Drugs and Catheter Ablation Techniques Show Promise? Systematic Review on Pharmacotherapy and Interventional Strategies
Table 2
Patients, etiology, end points, treatment effects, and adverse reactions in the Pivotal Phase III randomized controlled trials of the US Food and Drug Administration approved endothelin-1 receptor antagonists for the treatment of pulmonary arterial hypertension in adults.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BREATHE: Bosentan Randomized Trial of Endothelin Antagonist THErapy; EARLY: Endothelin Antagonist tRial in mildLY symptomatic pulmonary arterial hypertension patients; ARIES: Ambrisentan in pulmonary arterial hypertension, RandomIzed, double-blind, placebo-controlled, multicenter, efficacy study; SERAPHIN: Study with an Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Improve cliNical outcome; bid: twice daily; qd: once-daily; os: oral; sum of percentage may not be 100% for rounding to the nearest unit; 0.5 is rounded to the upper unit; IPAH: idiopathic pulmonary arterial hypertension; CTD: connective tissue disease; CHD: congenital heart disease (congenital systemic-to-pulmonary shunts); HIV: human immunodeficiency virus; NYHA: New York Heart Association; WHO: World Health Organization; 6MWD: 6 min walking distance; primary end point, time from the initiation of treatment to the first occurrence of a composite of death, atrioseptostomy, lung transplantation, initiation of prostanoids, or worsening of PAH; : mean (or median) change from baseline. |